SAN DIEGO, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com) announced today that the Company will present at two upcoming conferences.
Edward Cox, Vice President, Corporate Development, will present at The BIO-Europe 2012 Conference, being held at the CCH Congress Center in Hamburg, Germany. Mr. Cox's presentation will take place on Tuesday, November 13, 2012 at 10:00 a.m. Central European Time.
Steve Martin, Interim Chief Executive Officer and Chief Financial Officer will present at The Lazard Capital Markets 9th Annual Healthcare Conference, being held at The Pierre Hotel in New York City. Mr. Martin's presentation will take place on Wednesday, November 14, 2012 at 9:00 a.m. Eastern Time.
The Lazard presentation will be webcast and accessible online at http://wsw.com/webcast/lz13/apri/ and that presentation, along with the Bio-Europe presentation, will be available on the Company's website at www.apricusbio.com. A replay of the webcasts will be available on the Company's website for 14 days following the presentation.
About Apricus Biosciences, Inc.
Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, high-demand therapeutic classes. The Company has four approved products and has developed a strong pipeline of multiple late-stage product candidates. With commercial operations in both the U.S. and Europe (France), Apricus Bio generates revenues and growth from sales of its commercial products and by out-licensing, in certain territories, its pipeline products and NexACT® technology.
Apricus Bio's growth strategy is to acquire, develop, and commercialize new products through strategic partnerships. The Company currently has commercial partnerships with multiple large pharmaceutical companies including Novartis, Takeda, Abbott Laboratories, Sandoz, Warner Chilcott, and Bracco, and co-promotes multiple products in France.
Apricus Bio is headquartered in San Diego, CA and is publicly traded on the NASDAQ Capital Market under the ticker symbol APRI.
For further information on Apricus Bio, visit http://www.apricusbio.com, and for information on its subsidiary please visit http://www.nexmedusa.com. You can also receive information at http://twitter.com/apricusbio.
CONTACT: Apricus Bio Investor Relations: David Pitts Argot Partners 212-600-1902 email@example.com
Source:Apricus Biosciences, Inc.